Compounds and methods for kinase modulation, and indications therefor
US-2016176865-A1 · Jun 23, 2016 · US
Heterocyclic compounds and uses thereof
US10899761B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10899761-B2 |
| Application number | US-202016838383-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 2, 2020 |
| Priority date | Sep 21, 2015 |
| Publication date | Jan 26, 2021 |
| Grant date | Jan 26, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating an inflammatory response to a viral infection comprising administering to a subject in need thereof an effective amount of a compound of formula (II): or a pharmaceutically acceptable salt thereof, wherein R 1 is (C 1 -C 3 )alkyl. 2. A method for treating an inflammatory response to a viral infection comprising administering to a subject in need thereof an effective amount of a compound of formula: or a pharmaceutically acceptable salt thereof. 3. The method of claim 1 , wherein the inflammatory response is to a coronavirus infection. 4. The method of claim 2 , wherein the inflammatory response is to a coronavirus infection. 5. A method for treating synovial sarcoma comprising administering to a subject in need thereof an effective amount of a compound of formula (II): or a pharmaceutically acceptable salt thereof, wherein R 1 is (C 1 -C 3 )alkyl. 6. A method for treating synovial sarcoma comprising administering to a subject in need thereof an effective amount of a compound of formula: or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
- A61K31/444Primary
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title
- C07D471/04Primary
Ortho-condensed systems · CPC title
General protective or antinoxious agents · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10899761B2 cover?
- Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.
- Who is the assignee on this patent?
- Plexxikon Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/444. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).